NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Adicet Bio, Inc. (ACET) Stock Analysis

Adicet Bio, Inc. (ACET) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

ACET

$9.59

+$0.16 (+1.70%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ACET with… →

ACET Key Statistics

As of Sep 4, 2026
Trading
Open
$9.33
Previous Close
$9.43
Day's Range
9.26–9.76
52-Week Range
6.01–17.44
Volume
44.50K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.59
Valuation
Market Cap
$89.78M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−10.57
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$116.80M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
9.36M
1-Year Return
−15.94%
Dividend and dates
Earnings Date
November 5, 2026estimated
Avg Volume
90.42K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

ACET Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+13.90%
2025−45.30%
2024−49.10%
2023−78.86%
2022−48.89%
2021+24.48%
2020+34.71%
2019−82.71%
2018−48.93%

As of September 4, 2026.

ACET Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$116.80M—
2024$0.00−$117.12M—
2023$0.00−$142.66M—
2022$24.99M−$69.79M−279.3%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$122.11M−$116.80M—
2024$0.00—−$127.62M−$117.12M—
2023$0.00—−$132.58M−$142.66M—
2022$24.99M—−$72.55M−$69.79M−279.3%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ACET Valuation vs Biotechnology Median

Median of 656 stocks
MetricACETBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 9 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Adicet Bio, Inc. (ACET) at $89.78M. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 102 employees.

The 52-week range on file runs from $6.01 to $17.44. The most recent close on file for ACET is $9.59, dated September 4, 2026. That is +$0.16 (+1.70%) against the previous close. The latest close sits 59.57% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $116.80M. The reported profit margin is 0%. Earnings per share on a trailing basis come to −10.57.

Across the 4 fiscal years on file, revenue moves from $24.99M in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

Over the trailing twelve months the price has returned −15.94%. Measured over 5 years, that is −40.38% a year compounded. Beta against the wider market is reported at 1.59. Annualized volatility over the trailing 8 years is 92.48%.

Growth & Income

No dividend is on file for ACET.

The strongest complete calendar year on file is 2020 at +34.71%; the weakest is 2019 at −82.71%. Of the 8 complete calendar years on file, 2 finished higher. 2026 is still running; the price is +13.90% year to date.

Peer Comparison

Adicet Bio, Inc. (ACET) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Adicet Bio, Inc. ACET $89.78M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Adicet Bio, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Adicet Bio, Inc.

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops ADI-212, a gene-edited and armored clinical candidate that targets prostate-specific membrane antigen. The company was founded in 2014 and is based in Boston, Massachusetts.

Visit website →